Thermo Fisher Scientific (TMO)
(Delayed Data from NYSE)
$596.92 USD
+3.13 (0.53%)
Updated Oct 11, 2024 04:00 PM ET
After-Market: $596.52 -0.40 (-0.07%) 7:58 PM ET
3-Hold of 5 3
C Value D Growth D Momentum D VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$596.92 USD
+3.13 (0.53%)
Updated Oct 11, 2024 04:00 PM ET
After-Market: $596.52 -0.40 (-0.07%) 7:58 PM ET
3-Hold of 5 3
C Value D Growth D Momentum D VGM
Zacks News
Here's Why You Should Retain Haemonetics (HAE) Stocks for Now
by Zacks Equity Research
Investors are optimistic about Haemonetics (HAE) on a strong recovery across businesses, mainly at Hospital, and the initial Plasma Persona rollouts.
Medtronic's (MDT) INVOS System Gets FDA 510 (k) Clearance
by Zacks Equity Research
Medtronic's (MDT) INVOS 7100 system can deliver key signals to pediatric clinicians for making time-sensitive decisions
Avantor (AVTR) to Improve Biopharma Supply Chain With New Site
by Zacks Equity Research
Avantor's (AVTR) new logistics hub in Westminster is intended to support growth of single-use businesses.
The Zacks Analyst Blog Highlights: Berkshire Hathaway, Thermo Fisher Scientific, Salesforce, Nike and Texas Instruments
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Berkshire Hathaway, Thermo Fisher Scientific, Salesforce, Nike and Texas Instruments
Here's Why You Should Retain Catalent (CTLT) Stock for Now
by Zacks Equity Research
Investors continue to be optimistic about Catalent (CTLT) owing to its robust facility expansion activities and a slew of strategic deals.
Top Research Reports for Berkshire Hathaway, Thermo Fisher & salesforce
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Berkshire Hathaway Inc. (BRK.B), Thermo Fisher Scientific Inc. (TMO), and salesforce.com, inc. (CRM).
Here's Why You Should Hold on to NEOGEN (NEOG) Stock for Now
by Zacks Equity Research
Investors are optimistic about NEOGEN (NEOG) given robust sales growth in the Food Safety business and impressive international performance.
Here's Why You Should Retain STERIS (STE) Stock for Now
by Zacks Equity Research
Investors are optimistic about STERIS (STE) owing to strong segmental growth and bullish 2022 outlook.
Thermo Fisher Scientific (TMO) Gains As Market Dips: What You Should Know
by Zacks Equity Research
In the latest trading session, Thermo Fisher Scientific (TMO) closed at $661.25, marking a +0.84% move from the previous day.
FDA Approves Intuitive Surgical's (ISRG) Latest SureForm Stapler
by Zacks Equity Research
Intuitive Surgical's (ISRG) newest stapler is expected to result in better surgical outcomes.
NEOGEN (NEOG) Gains on 3M's Food Safety Arm Merger Deal
by Zacks Equity Research
According to NEOGEN (NEOG), apart from the United States and Europe, substantial interest among developing nations to improve food safety presents significant growth potential for the combined company.
Walgreens (WBA), Village MD Plan to Expand Into San Antonio
by Zacks Equity Research
Walgreens (WBA) and VillageMD to improve access to overall care for patients with chronic conditions by opening nine new Village Medical at Walgreens primary care practices in San Antonio.
Zacks Industry Outlook Highlights: Thermo Fisher Scientific, STERIS and Accuray
by Zacks Equity Research
Zacks Industry Outlook Highlights: Thermo Fisher Scientific, STERIS and Accuray
Is Franklin LibertyQ U.S. Equity ETF (FLQL) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for FLQL
Veeva's (VEEV) Data Cloud to Aid PharmaEssentia's New Product
by Zacks Equity Research
Adoption of Veeva Systems' (VEEV) cloud applications is likely to significantly boost its Commercial Cloud business.
3 Top Medical Instruments Stocks to Counter Industry Headwinds
by Urmimala Biswas
The Zacks Medical - Instruments industry is growing on COVID-support business gains. TMO, STE and ARAY are set to gain the most. Yet, demand for base business is on the decline with the new COVID variant disrupting the trend.
Illumina (ILMN) to Develop Synthetic Genomic Data With New Pact
by Zacks Equity Research
Illumina's (ILMN) recent collaboration will allow it to leverage the best-quality synthetic data to remove privacy bottlenecks and accelerate the development of precision medicine.
Here's Why You Should Retain Charles River (CRL) Stock for Now
by Zacks Equity Research
Investors are optimistic about Charles River (CRL) on acquisitions of Cognate BioServices and Vigene Biosciences.
Should Franklin LibertyQ U.S. Equity ETF (FLQL) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for FLQL
Here's Why You Should Retain Veeva Systems (VEEV) Stock for Now
by Zacks Equity Research
Investors continue to be optimistic about Veeva Systems (VEEV) owing to its strong product portfolio.
Study Favors Masimo's (MASI) SedLine for Better Patient Outcome
by Zacks Equity Research
Masimo's (MASI) SedLine is expected to aid in the early identification of patients who are at risk of developing POD.
Here's Why You Should Retain Ecolab (ECL) Stock Right Now
by Zacks Equity Research
Ecolab (ECL) continues to gain traction from a solid product portfolio and segmental strength. However, segmental weakness remains a woe.
Veeva Systems' (VEEV) Buyout to Bolster Clinical Offering
by Zacks Equity Research
Veeva Systems' (VEEV) Veracity Logic buyout can help companies to simplify complex processes and speed up clinical trials.
CVS Health (CVS) Outlines Growth Strategy, Initiates 2022 View
by Zacks Equity Research
CVS Health's (CVS) new strategy capitalizes on the considerable opportunity to make health care more convenient, personalized and affordable for consumers.
McKesson (MCK) Hits 52-Week High: What's Aiding the Stock?
by Zacks Equity Research
Investors are optimistic about McKesson's (MCK) strength in its Biologics business.